185 related articles for article (PubMed ID: 18437302)
1. Methods to assay inhibitors of DNA gyrase and topoisomerase IV activities.
Fisher LM; Pan XS
Methods Mol Med; 2008; 142():11-23. PubMed ID: 18437302
[TBL] [Abstract][Full Text] [Related]
2. Novel symmetric and asymmetric DNA scission determinants for Streptococcus pneumoniae topoisomerase IV and gyrase are clustered at the DNA breakage site.
Leo E; Gould KA; Pan XS; Capranico G; Sanderson MR; Palumbo M; Fisher LM
J Biol Chem; 2005 Apr; 280(14):14252-63. PubMed ID: 15659402
[TBL] [Abstract][Full Text] [Related]
3. Probing the differential interactions of quinazolinedione PD 0305970 and quinolones with gyrase and topoisomerase IV.
Pan XS; Gould KA; Fisher LM
Antimicrob Agents Chemother; 2009 Sep; 53(9):3822-31. PubMed ID: 19564360
[TBL] [Abstract][Full Text] [Related]
4. Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.
Yague G; Morris JE; Pan XS; Gould KA; Fisher LM
Antimicrob Agents Chemother; 2002 Feb; 46(2):413-9. PubMed ID: 11796351
[TBL] [Abstract][Full Text] [Related]
5. Distribution of gyrase and topoisomerase IV on bacterial nucleoid: implications for nucleoid organization.
Hsu YH; Chung MW; Li TK
Nucleic Acids Res; 2006; 34(10):3128-38. PubMed ID: 16757578
[TBL] [Abstract][Full Text] [Related]
6. Fluoroquinolones inhibit preferentially Streptococcus pneumoniae DNA topoisomerase IV than DNA gyrase native proteins.
Fernandez-Moreira E; Balas D; Gonzalez I; de la Campa AG
Microb Drug Resist; 2000; 6(4):259-67. PubMed ID: 11272253
[TBL] [Abstract][Full Text] [Related]
7. Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.
Strahilevitz J; Hooper DC
Antimicrob Agents Chemother; 2005 May; 49(5):1949-56. PubMed ID: 15855518
[TBL] [Abstract][Full Text] [Related]
8. Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins.
Pan XS; Yague G; Fisher LM
Antimicrob Agents Chemother; 2001 Nov; 45(11):3140-7. PubMed ID: 11600369
[TBL] [Abstract][Full Text] [Related]
9. Topoisomerase IV, not gyrase, decatenates products of site-specific recombination in Escherichia coli.
Zechiedrich EL; Khodursky AB; Cozzarelli NR
Genes Dev; 1997 Oct; 11(19):2580-92. PubMed ID: 9334322
[TBL] [Abstract][Full Text] [Related]
10. Ciprofloxacin dimers target gyrase in Streptococcus pneumoniae.
Gould KA; Pan XS; Kerns RJ; Fisher LM
Antimicrob Agents Chemother; 2004 Jun; 48(6):2108-15. PubMed ID: 15155208
[TBL] [Abstract][Full Text] [Related]
11. Dual activity of fluoroquinolones against Streptococcus pneumoniae: the facts behind the claims.
Smith HJ; Nichol KA; Hoban DJ; Zhanel GG
J Antimicrob Chemother; 2002 Jun; 49(6):893-5. PubMed ID: 12039880
[No Abstract] [Full Text] [Related]
12. Dual inhibition of Staphylococcus aureus DNA gyrase and topoisomerase IV activity by phenylalanine-derived (Z)-5-arylmethylidene rhodanines.
Werner MM; Patel BA; Talele TT; Ashby CR; Li Z; Zauhar RJ
Bioorg Med Chem; 2015 Sep; 23(18):6125-37. PubMed ID: 26320664
[TBL] [Abstract][Full Text] [Related]
13. Novel quinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV.
Mitton-Fry MJ; Brickner SJ; Hamel JC; Brennan L; Casavant JM; Chen M; Chen T; Ding X; Driscoll J; Hardink J; Hoang T; Hua E; Huband MD; Maloney M; Marfat A; McCurdy SP; McLeod D; Plotkin M; Reilly U; Robinson S; Schafer J; Shepard RM; Smith JF; Stone GG; Subramanyam C; Yoon K; Yuan W; Zaniewski RP; Zook C
Bioorg Med Chem Lett; 2013 May; 23(10):2955-61. PubMed ID: 23566517
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914.
Kern G; Palmer T; Ehmann DE; Shapiro AB; Andrews B; Basarab GS; Doig P; Fan J; Gao N; Mills SD; Mueller J; Sriram S; Thresher J; Walkup GK
J Biol Chem; 2015 Aug; 290(34):20984-20994. PubMed ID: 26149691
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and antibacterial evaluation of new quinoline-1,3,4-oxadiazole and quinoline-1,2,4-triazole hybrids as potential inhibitors of DNA gyrase and topoisomerase IV.
Hofny HA; Mohamed MFA; Gomaa HAM; Abdel-Aziz SA; Youssif BGM; El-Koussi NA; Aboraia AS
Bioorg Chem; 2021 Jul; 112():104920. PubMed ID: 33910078
[TBL] [Abstract][Full Text] [Related]
16. What makes a type IIA topoisomerase a gyrase or a Topo IV?
Hirsch J; Klostermeier D
Nucleic Acids Res; 2021 Jun; 49(11):6027-6042. PubMed ID: 33905522
[TBL] [Abstract][Full Text] [Related]
17. Bimodal Actions of a Naphthyridone/Aminopiperidine-Based Antibacterial That Targets Gyrase and Topoisomerase IV.
Gibson EG; Oviatt AA; Cacho M; Neuman KC; Chan PF; Osheroff N
Biochemistry; 2019 Nov; 58(44):4447-4455. PubMed ID: 31617352
[TBL] [Abstract][Full Text] [Related]
18. Streptococcus pneumoniae DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones.
Pan XS; Fisher LM
Antimicrob Agents Chemother; 1999 May; 43(5):1129-36. PubMed ID: 10223925
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of DNA gyrase and DNA topoisomerase IV of Staphylococcus aureus and Escherichia coli by aminocoumarin antibiotics.
Alt S; Mitchenall LA; Maxwell A; Heide L
J Antimicrob Chemother; 2011 Sep; 66(9):2061-9. PubMed ID: 21693461
[TBL] [Abstract][Full Text] [Related]
20. Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro.
Heaton VJ; Ambler JE; Fisher LM
Antimicrob Agents Chemother; 2000 Nov; 44(11):3112-7. PubMed ID: 11036032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
